Sandra Garcet
Overview
Explore the profile of Sandra Garcet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
970
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aguero R, Buchanan K, Navarrete-Dechent C, Marghoob A, Stein J, Landy M, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272935
Incorporation of dermoscopy and artificial intelligence (AI) is improving healthcare professionals' ability to diagnose melanoma earlier, but these algorithms often suffer from a "black box" issue, where decision-making processes are...
2.
Shishido-Takahashi N, Garcet S, Cueto I, Miura S, Li X, Rambhia D, et al.
J Invest Dermatol
. 2024 Jul;
145(3):536-547.e7.
PMID: 39038532
Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is difficult to control, and its mechanism remains unclear. Hepatocyte GF (HGF) has been reported to be significantly upregulated in the...
3.
Renert-Yuval Y, Gonzalez J, Garcet S, Williams S, Moreno A, Krueger J
Exp Dermatol
. 2024 Jul;
33(7):e15129.
PMID: 38984465
Hidradenitis suppurativa (HS) is an inflammatory skin disease characterized by painful nodules, abscesses and purulent secretions in intertriginous regions. Intense pruritus frequently accompanies HS lesions, adding further discomfort for patients....
4.
Williams S, Garcet S, Hur H, Miura S, Gonzalez J, Navrazhina K, et al.
Exp Dermatol
. 2024 Apr;
33(5):e15087.
PMID: 38685821
Hidradenitis Suppurativa (HS) is a chronic autoinflammatory skin disease with activated keratinocytes, tunnel formation and a complex immune infiltrate in tissue. The HS microbiome is polymicrobial with an abundance of...
5.
Tehlirian C, Peeva E, Kieras E, Scaramozza M, Roberts E, Singh R, et al.
Lancet Rheumatol
. 2024 Jan;
3(3):e204-e213.
PMID: 38279383
Background: Blockade of tyrosine kinase 2 (TYK2) signalling has previously shown therapeutic potential in the treatment of psoriasis. The primary objective of this study was to assess the safety and...
6.
Navrazhina K, Renert-Yuval Y, Khattri S, Hamade H, Meariman M, Andrews E, et al.
J Am Acad Dermatol
. 2023 Dec;
90(4):749-758.
PMID: 38049071
Background: Hidradenitis suppurativa (HS) has a high unmet need for better treatments. Biopsies are considered the gold standard for studying molecular alterations in skin. A reproducible, minimally invasive approach is...
7.
Kim J, Lee J, Li X, Kunjravia N, Rambhia D, Cueto I, et al.
Front Immunol
. 2023 Oct;
14:1250504.
PMID: 37781383
Durable psoriasis improvement has been reported in a subset of psoriasis patients after treatment withdrawal of biologics blocking IL-23/Type 17 T-cell (T17) autoimmune axis. However, it is not well understood...
8.
Laser capture microdissection provides a novel molecular profile of human primary cutaneous melanoma
Navrazhina K, Garcet S, Williams S, Gulati N, Kiecker F, Frew J, et al.
Pigment Cell Melanoma Res
. 2023 Sep;
37(1):81-89.
PMID: 37776566
Melanoma accounts for the majority of skin cancer-related mortality, highlighting the need to better understand melanoma initiation and progression. In-depth molecular analysis of neoplastic melanocytes in whole tissue biopsies may...
9.
Krueger J, Langley R, Nigen S, Kasparek T, Di Comite G, Ortmann C, et al.
Exp Dermatol
. 2023 Jun;
32(10):1834-1847.
PMID: 37272375
Interleukin (IL)-23-independent IL-17A production has been suggested to be involved in persistent manifestations of psoriatic disease, including anti-IL-12/23-refractory psoriatic plaques; this study aimed to test this hypothesis by investigating the...
10.
Campbell K, Li K, Yang F, Branigan P, Elloso M, Benson J, et al.
Immunohorizons
. 2023 Apr;
7(4):273-285.
PMID: 37071038
Given the key role of the IL-23/Th17 axis in the pathogenesis of moderate-to-severe plaque psoriasis, several specific inhibitors of the p19 subunit of IL-23 have been approved to treat this...